Clinical Trial Update: Initiation of ARNi and SGLT2i in Patients With HFrEF [Phase 4]

View source ↗

Summary

Phase 4 trial completion evaluating initiation of an ARNi and an SGLT2 inhibitor in patients with heart failure with reduced ejection fraction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Dapagliflozin (dapagliflozin)
• Empagliflozin (empagliflozin)
• Sacubitril/Valsartan (sacubitril/valsartan)

Snippet

Sponsor: Universidade do Porto | Conditions: Heart Failure With Reduced Ejection Fraction | Phase 4 | Status: COMPLETED